Sociedad Española de Reumatología-ko ikertzaileekin lankidetzan egindako argitalpenak (35)

2024

  1. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis

    European Journal of Clinical Investigation, Vol. 54, Núm. 2

2023

  1. Development of a web tool to calculate the cumulative dose of glucocorticoids

    Reumatologia Clinica, Vol. 19, Núm. 1, pp. 1-5

  2. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  3. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

    Advances in Rheumatology, Vol. 63, Núm. 1

  4. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

    Musculoskeletal Care, Vol. 21, Núm. 1, pp. 189-197

2022

  1. Prevalence of gout in the adult general population in Spain: Estimating the proportion of undiagnosed cases

    Joint Bone Spine, Vol. 89, Núm. 1

  2. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

    Rheumatology International, Vol. 42, Núm. 6, pp. 1085-1096

  3. The reality of Rheumatology in Spain and its autonomous communities before the pandemic

    Reumatologia Clinica, Vol. 18, Núm. 8, pp. 486-489

2021

  1. Comment on: Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Reply

    Rheumatology (Oxford, England), Vol. 60, Núm. 3, pp. e120-e121

  2. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry

    Clinical Rheumatology, Vol. 40, Núm. 10, pp. 3979-3988

  3. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study

    Reumatologia Clinica, Vol. 17, Núm. 8, pp. 461-470

  4. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: Results from the COVIDSER study

    RMD Open, Vol. 7, Núm. 3

2020

  1. Association between periodontitis and anti-citrullinated protein antibodies in rheumatoid arthritis patients: A cross-sectional study

    Arthritis Research and Therapy, Vol. 22, Núm. 1

  2. Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study

    Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170

  3. Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study

    PLoS ONE, Vol. 15, Núm. 6

  4. Prevalence of Sjögren’s syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases

    Scientific Reports, Vol. 10, Núm. 1

  5. Prevalence of ankylosing spondylitis in Spain: EPISER2016 Study

    Scandinavian Journal of Rheumatology, Vol. 49, Núm. 3, pp. 210-213

  6. Prevalence of fibromyalgia and associated factors in Spain

    Clinical and experimental rheumatology, Vol. 38, Núm. 1, pp. 47-52

  7. Prevalence of systemic lupus erythematosus in Spain: Higher than previously reported in other countries?

    Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2556-2562

  8. The prevalence of rheumatoid arthritis in Spain

    Scientific Reports, Vol. 10, Núm. 1